
|Articles|September 15, 2002
Macugen research: Enrollment ends early in trials for wet AMD drug
New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Non-invasive electrical stimulation therapy for intermediate dry AMD: improved retinal health and visual acuity
2
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
3
Subramanian, MD: anti-VEGF linked to kidney function decline
4
Retina Society 2026: Could statins reduce PVR risk after RD repair?
5











